Octahydroindolo[2,3-a]quinolizines and 3,4-dihydro-beta-carbolines as new inhibitors of human platelet aggregation.
Octahydroindolo[2,3-a]quinolizines and 3,4-dihydro-beta-carbolines proved to be powerful inhibitors of human platelet aggregation. They exhibited IC50 values two magnitudes lower than those of the commonly used cyclo-oxygenase inhibitors and no influence upon the routine parameters of blood coagulation was observed in vitro. Some of the compounds increased the vascular production of prostacyclin.
Blaskó
G
G
Central Research Institute for Chemistry, Hungarian Academy of Sciences, Budapest.
Blaskó
G
G
Szántay
C
C
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001013:Aorta, Thoracic / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D002243:Carbolines / Q000138:chemical synthesis*; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D066298:In Vitro Techniques; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D011807:Quinolizines / Q000138:chemical synthesis*
D002243:Carbolines; D011807:Quinolizines; C049049:1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)quinolizine; D000244:Adenosine Diphosphate; D011464:Epoprostenol